ceroid lipofuscinosis


Also found in: Dictionary.

Bat·ten dis·ease

(bat'ĕn),
cerebral sphingolipidosis, late juvenile type.

ceroid lipofuscinosis

see ceroid lipofuscinosis.
References in periodicals archive ?
Key words: neuronal ceroid lipofuscinosis, neurodegenerative disorders, NCL, waterfowl, avian, mallard duck, Anas platyrhynchos
Diagnostic value of electron microscopy in a case of juvenile neuronal ceroid lipofuscinosis.
StemCells says the proposed Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC as a treatment of infantile and late-infantile neuronal ceroid lipofuscinosis.
Detection of eight novel palmitoyl protein thicesterase (PPT) mutations underlying infantile neuronal ceroid lipofuscinosis (INCL; CLN1).
In the paper entitled "Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis with CNS Administration of a Serotype 2 Adeno-associated virus expressing the CLN2 cDNA," the authors report that over an 18-month period, assessment using a neurologic rating scale demonstrated significant slowing of disease progression in the treated, compared to the untreated children.
The proposed Phase I trial is designed to investigate the safety of HuCNS-SC in the treatment of infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), the most severe forms of a group of disorders commonly referred to as Batten disease.
Mutations in the palmitoyl protein thicesterase gene causing infantile neuronal ceroid lipofuscinosis.
NASDAQ: STEM) today provided an update on the ongoing clinical development program of its proprietary HuCNS-SC([R]) product candidate (purified human neural stem cells) for neuronal ceroid lipofuscinosis (NCL), often referred to as Batten disease.
The Company has previously reported on the preclinical efficacy of its cells for treatment of Neuronal Ceroid Lipofuscinosis, a lysosomal storage disease commonly referred to as Batten's Disease.
In September 2009, StemCells announced the publication of preclinical data demonstrating the therapeutic potential of its HuCNS-SC([R]) product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL), often referred to as Batten disease, a fatal neurodegenerative disorder in children.
will present preclinical data from a transplant study using the Company's proprietary human neural stem cells (CNS-SC) in Neuronal Ceroid Lipofuscinosis, a lysosomal storage disease commonly referred to as Batten Disease or NCL.